0001209191-22-003084.txt : 20220112
0001209191-22-003084.hdr.sgml : 20220112
20220112171638
ACCESSION NUMBER: 0001209191-22-003084
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220110
FILED AS OF DATE: 20220112
DATE AS OF CHANGE: 20220112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bandari Jathin
CENTRAL INDEX KEY: 0001903622
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 22527223
MAIL ADDRESS:
STREET 1: C/O PROTORA THERAPEUTICS, INC.
STREET 2: 345 PARK AVENUE SOUTH, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-10
0
0001359931
Protara Therapeutics, Inc.
TARA
0001903622
Bandari Jathin
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK
NY
10010
0
1
0
0
Chief Medical Officer
Common Stock
2022-01-10
4
A
0
13500
0.00
A
13500
D
Stock Option (Right to Buy)
6.27
2022-01-10
4
A
0
81000
0.00
A
2032-01-09
Common Stock
81000
81000
D
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 10, 2022.
25% of the shares vest on the one year anniversary of January 10, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
/s/ Mary Grendell, Attorney-in-Fact
2022-01-10